Memantine Augmentation in Obsessive-Compulsive Disorder

Phase

1/2

Condition

Obsessive-compulsive Disorder

Anxiety Disorders

Panic Disorders

Treatment

N/A

Clinical Study ID

NCT00264238

SUSPO34313

Ages > 18
All Genders

Study Summary

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

at least 18 years of age
suffering from OCD
Y-BOCS score of 18 or greater
taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion

Exclusion Criteria:

diagnosed with a mental disorder other than OCD
taking tiagabine or pregabalin
having had a previous trial of memantine
receiving therapy for OCD
substance abuse in the last 6 months
personality disorders sufficiently severe to interfere with study participation

Study Design

January 01, 2006

June 30, 2008

Study Description

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer's Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain's specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

Connect with a study center

Stanford University School of Medicine
Stanford, California 94305
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.